UNG THƯ TUYẾN GIÁP THỂ BIỆT HÓA KHÁNG TRỊ  VỚI IOD 131 TỪ LÝ THUYẾT ĐẾN THỰC HÀNH LÂM SÀNG

Thành Công Nguyễn; Đình Tuyển Vũ; Văn Nhụ Đậu

doi:10.59354/ydth175.2022.60

Keywords:

Radioactive iodine refractory, differentiated thyroid cancer

Abstract

Radioactive iodine - refractory occurs in 15% of patients with differentiated thyroid cancer and greatly affects survival prognosis. In general, radioactive iodine - refractory is divided into four groups based on the I-131 uptake. Ttreatment for this group of patients with chemotherapy, radiation therapy, targeted therapy... is still controversial in clinical practice, especially in advanced metastasis cases. The objective of this article is to generalize, and evaluate the complexities of the diagnostic and therapeutic process of radioactive iodine – refractory.

References

Nguyễn Thành Công, Nguyễn Minh Tính, Đào Tiến Mạnh, Vũ Đình Tuyển (2013), Đánh giá hiệu quả điều trị ung thư tuyến giáp thể biệt hóa sau phẫu thuật bằng I-131 tại Bệnh viện 175, Tạp chí Y Dược Lâm sàng 108, tập 8, tr: 168 – 172.

TrầnVăn Thiệp, Trần Đặng Ngọc Linh, Nguyễn Thành Công (2013), Hiệu quả diệt giáp bằng I-131liều thấp sau phẫu thuật ung thư tuyến giáp thể biệt hóa, tạp chí ung thư học Việt Nam, số 4, Tr: 119 – 125.

ATA guidelines 2015, Recommendation 91 - 95, pp. 81 – 86.

Bernard DM, Sperduto PW, Souhami L et al. Sterotactic radiosurgery in the management of brain metastases from primary thyroid cancers. J Neuroonco. 2010; 98(2) 249-52.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228 – 47.

Harada T, Nishikawa Y, Suzuki T, Ito K, Kaba S (1971), Bleomicin treatment for cancer of the throid , Am J Surg 122, pp. 53 – 57.

Leboulleux S, Bastholt L, Krause T et al (2012), Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double blind, phase 2 trial, Lancet oncol 13, pp. 897 – 905.

Orita Y, Sugitani I et al. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid cancer. Surgery. 2010; 147(3): 424-31.

Robbin RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM (2006), Real time prognosis for metastatic throid carcinoma based on [18F] fluoro-2-deoxy D-glucose-positron emission tomography scanning, J Clin Endocrinol Metab 91, pp. 498 – 505.

Schutz FA, Je Y, Richards CJ, choueiri TK (2012), Meta-analysis of randomized controlled trials for incidence and risk of treatment – related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors, J Clinl Oncol 30, pp. 871 – 877.